Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation and Depletion (2022 - 2025)

Dianthus Therapeutics has reported Depreciation and Depletion over the past 4 years, most recently at $27000.0 for Q3 2025.

  • Quarterly results put Depreciation and Depletion at $27000.0 for Q3 2025, up 8.0% from a year ago — trailing twelve months through Sep 2025 was $110000.0 (up 22.22% YoY), and the annual figure for FY2024 was $96000.0, up 43.28%.
  • Depreciation and Depletion for Q3 2025 was $27000.0 at Dianthus Therapeutics, down from $30000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for DNTH hit a ceiling of $30000.0 in Q2 2025 and a floor of $11000.0 in Q4 2022.
  • Median Depreciation and Depletion over the past 4 years was $22500.0 (2024), compared with a mean of $21500.0.
  • Biggest five-year swings in Depreciation and Depletion: soared 81.82% in 2023 and later rose 8.0% in 2025.
  • Dianthus Therapeutics' Depreciation and Depletion stood at $11000.0 in 2022, then soared by 81.82% to $20000.0 in 2023, then grew by 30.0% to $26000.0 in 2024, then grew by 3.85% to $27000.0 in 2025.
  • The last three reported values for Depreciation and Depletion were $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $27000.0 (Q1 2025) per Business Quant data.